Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I
Key claim: The DEA proposes listing five tryptamine hallucinogens as Schedule I drugs, which would make manufacturing, distributing, importing, exporting, researching, or possessing them illegal except under the tightest federal controlled-substance rules.
Abstract
(Proposed Rule · Justice Department, Drug Enforcement Administration) The Drug Enforcement Administration proposes placing five tryptamine hallucinogens, 4-hydroxy-N,N-diisopropyltryptamine (other names: 4-OH-DiPT; 3-(2-(diisopropylamino)ethyl)-1H-indol-4- ol), 5-methoxy-alpha-methyltryptamine (other names: 5-MeO-AMT; 1-(5- methoxy-1H-indol-3-yl)propan-2-amine), 5-methoxy-N-methyl-N- isopropyltryptamine (other names: 5-MeO-MiPT; N-(2-(5-methoxy-1H-indol- 3-yl)ethyl)-N-methylpropan-2-amine), 5-methoxy-N,N-diethyltryptamine (other names: 5-MeO-DET; N,N-diethyl-2-(5-methoxy-1H-indol-3- yl)ethanamine), and N,N-diisopropyltryptamine (other names: DiPT; N-(2- (1H-indol-3-yl)ethyl)-N-isopropylpropan-2-amine), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specific tryptamine hallucinogens.
Why this matters
Schedule I placement is the most restrictive federal drug classification, requiring special DEA registration for any legitimate research and criminalizing possession outside those narrow channels. Adding these five tryptamines mirrors DEA’s steady cadence of scheduling novel psychoactive substances, and would foreclose their use as research chemicals or in clinical investigation absent a Schedule I registration.